Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY 3563254
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BAY 3563254 (also known as 225Ac-PSMA-Trillium) is an investigational targeted alpha therapy developed by Bayer for the treatment of advanced metastatic castration-resistant prostate cancer (mCRPC). It consists of a novel small molecule that targets prostate-specific membrane antigen (PSMA), conjugated to the alpha-emitting radioisotope actinium-225. Upon intravenous administration, BAY 3563254 binds specifically to PSMA-expressing tumor cells, delivering cytotoxic alpha radiation directly to these cells and thereby inducing tumor cell death while aiming to minimize damage to normal tissues. The drug features a customized albumin-binding moiety designed to enhance therapeutic efficacy and reduce off-target toxicity, particularly in organs such as salivary glands. As of mid-2025, it is being evaluated in first-in-human Phase I clinical trials for safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with mCRPC[1][2][5][6].
- Brand names
- BAY3563254BAY-3563254BAY 3563254225Ac-PSMA-Trillium
- Other names
- actinium Ac 225-PSMA-trillium
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on BAY 3563254.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY 3563254.